Skip to content Skip to navigation

Company testing nasal-spray alternative to overdose injection

December 5, 2013
by Gary A. Enos, Editor
| Reprints

A London-based biopharmaceutical company is reporting promising results from a two-week trial of an intranasal alternative to the naloxone injections that have become a prevalent intervention for opioid overdose patients.

Lightlake Therapeutics, Inc., conducted the clinical trial in September and October in partnership with the National Institute on Drug Abuse (NIDA), and reported this week that its nasal spray version of naloxone appears to enter the bloodstream at least as quickly as the injections that are now commonly used in hospitals and among first responders.

The company, which also holds a patent on its technology for the treatment of binge eating disorder, is seeking to submit a New Drug Application (NDA) with the Food and Drug Administration (FDA) next year.

“Given our collaboration with NIDA and current understanding of the regulatory pathway with respect to our prospective opioid overdose reversal product, we anticipate incurring relatively low costs to reach an NDA submission with the FDA,” Lightlake chief financial officer Kevin Pollack said in a news release.      

Topics